The growth of Viagra and its effect on the medicinal landscape presents a complicated question for shareholders. While the initial sales statistics were astounding, the intellectual property has lapsed, leading to a wave of generic alternatives that are eroding earnings. Furthermore, the market is facing challenges related to demographic trends … Read More